Today we’re excited to announce a new collaboration with UCB, a multinational biopharma company headquartered in Brussels, Belgium, with the launch of a digital health trial for myasthenia gravis, a neuromuscular disease that can lead to impaired speech, blurred vision, difficulty swallowing, and other symptoms.
Welcome to our blog
Recent advancements for COVID-19 vaccines are promising, at the same time, COVID-19 hospitalization rates are spiking across the country. In today’s environment, health and safety guidelines will continue to evolve and employers need support to quickly adapt their return to work programs by location and industry.
The pandemic has directed a spotlight on how digital tools can lighten the load on healthcare systems by shortening the time between seeing a doctor or a therapist. In telehealth, we’ve seen digital transformation accelerate rapidly in 2020. According to a Definitive Healthcare survey, 23% of health executives agree that increased telehealth usage is the trend that will have the most significant impact on the healthcare industry over the next year.
Coronavirus, pandemic and COVID-19 are still relatively new additions to our daily vocabularies. We now live in a world that seems much slower, full of constant browser refreshes for updates, nostalgia for the way things were, and carefully planned outings to the grocery store. Yet, a competitive race is underway, as our futures are now tied to the breakthroughs made by medical researchers, and importantly, to the people participating in clinical trials.
Passport is a ready-to-use return to work solution for employers of all sizes. With an intuitive self-attestation app and a powerful administrator dashboard, Passport allows your team to return to the work with ease. At doc.ai, our team has focused on building a plug-and-play solution that doesn’t require complex technical integrations or engineering resources, but instead, allows you to safely and efficiently manage your team’s return to the workplace.
Much like any other industry in the modern world, the healthcare industry is growing rapidly with health data doubling every 73 days.
Tracked individualized reports are now available at the end of the trial in the doc.ai app. Medical research can feel like a black box when you enroll in clinical studies. Why? Because you share your data and personal information for months without any access to it or even the possibility to share it with your healthcare provider. It doesn’t have to be that way anymore.
doc.ai has seen awesome demand for a new kind of prospective research study called a data trial. Our first data trial was launched this past fall and called “Can Artificial Intelligence Predict Your Risk of Allergies?”
There seems to be a consensus nowadays that medical information in the United States doubles every 73 days estimated to arrive at hefty 2.3 zettabytes (ZB) by 2020. But even these optimistic calculations do not take into account what happened this month when Google announced “Towards Federated Learning At Scale: System Design” and happily said:
Review of Eric Topol's upcoming "Deep Medicine"
For his third book, Eric Topol produced a time capsule for Deep Medicine AD 2019: a particular time in the history of healthcare when everything was still possible, but we had to make a choice.